Company intelligence / Profile preview
GAT Biosciences
Barcelona, Catalonia, Spaingatbiosciences.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
GAT Biosciences develops next-generation oral biopharmaceuticals using engineered microalgae as sustainable biofactories. Their lead candidate, GB-AF-004—an anti-inflammatory oral biologic for IBD—is entering preclinical development. The company aims to convert traditionally injected blockbuster biologicals into convenient oral pills with enhanced stability in the gastrointestinal tract. They have received a Seal of Excellence from the EIC Accelerator Program.
- Therapeutic areas
- GastroenterologyInfectious Diseases
- Modalities
- Oral biologics (recombinant proteins/antibodies)Topical biologics (potentially)Inhaled biologics (potentially)
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Not specifically listed; has received support from European innovation programs.
Beyond the preview
Go deeper on GAT Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GAT Biosciences.